EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

NCT06525298 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Homologous Recombination Deficiency
HRR Deficiency

Interventions

DRUG: EIS-12656
DRUG: Olaparib
DRUG: Trastuzumab deruxtecan

Sponsor

Eisbach Bio GmbH